Jacobs Levy Equity Management’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-581,753
| Closed | -$5.31M | – | 1099 |
|
|
2025
Q2 | $5.31M | Sell |
581,753
-124,637
| -18% | -$917K | 0.02% | 422 |
|
|
2025
Q1 | $5.62M | Sell |
706,390
-416,918
| -37% | -$3.05M | 0.02% | 442 |
|
|
2024
Q4 | $6.1M | Sell |
1,123,308
-136,709
| -11% | -$836K | 0.02% | 390 |
|
|
2024
Q3 | $9.1M | Sell |
1,260,017
-165,361
| -12% | -$1.51M | 0.04% | 339 |
|
|
2024
Q2 | $15.5M | Buy |
1,425,378
+870,165
| +157% | +$11.1M | 0.06% | 270 |
|
|
2024
Q1 | $10.4M | Sell |
555,213
-187,645
| -25% | -$4.33M | 0.05% | 293 |
|
|
2023
Q4 | $16.1M | Buy |
742,858
+351,627
| +90% | +$6.97M | 0.08% | 237 |
|
|
2023
Q3 | $8.05M | Buy |
+391,231
| New | +$11.3M | 0.05% | 290 |
|
|
2022
Q2 | – | Sell |
-85,572
| Closed | -$2.83M | – | 1076 |
|
|
2022
Q1 | $2.83M | Sell |
85,572
-133,479
| -61% | -$5.02M | 0.02% | 547 |
|
|
2021
Q4 | $9.32M | Buy |
219,051
+169,210
| +339% | +$7.08M | 0.06% | 319 |
|
|
2021
Q3 | $2.21M | Buy |
+49,841
| New | +$2.29M | 0.01% | 598 |
|
|
2021
Q2 | – | Sell |
-12,520
| Closed | -$937K | – | 1105 |
|
|
2021
Q1 | $937K | Sell |
12,520
-222,419
| -95% | -$18.2M | 0.01% | 749 |
|
|
2020
Q4 | $20.3M | Sell |
234,939
-23,880
| -9% | -$1.76M | 0.18% | 138 |
|
|
2020
Q3 | $15.8M | Buy |
258,819
+2,544
| +1% | +$129K | 0.16% | 142 |
|
|
2020
Q2 | $10.7M | Buy |
256,275
+209,759
| +451% | +$7.61M | 0.12% | 206 |
|
|
2020
Q1 | $1.34M | Buy |
46,516
+41,062
| +753% | +$2.38M | 0.02% | 561 |
|
|
2019
Q4 | $394K | Buy |
+5,454
| New | +$671K | ﹤0.01% | 815 |
|
|
2018
Q2 | – | Sell |
-2,150
| Closed | -$346K | – | 1088 |
|
|
2018
Q1 | $346K | Buy |
+2,150
| New | +$365K | 0.01% | 841 |
|
|
2016
Q4 | – | Sell |
-23,560
| Closed | -$1.08M | – | 1044 |
|
|
2016
Q3 | $1.08M | Sell |
23,560
-35,110
| -60% | -$1.43M | 0.02% | 562 |
|
|
2016
Q2 | $1.77M | Sell |
58,670
-2,050
| -3% | -$68.4K | 0.04% | 450 |
|
|
2016
Q1 | $1.95M | Buy |
+60,720
| New | +$2.14M | 0.04% | 415 |
|
Other funds holding SAGE
IA
HNB
Jacobs Levy Equity Management's SAGE Position: Q3 2025 in Review
Jacobs Levy Equity Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 581,753 shares — an estimated $5.31M sold.
Jacobs Levy Equity Management first reported a position in SAGE in Q1 2016 and held it in 21 quarters. The position peaked at $20.3M in Q4 2020. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Jacobs Levy Equity Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Jacobs Levy Equity Management sold 581,753 Sage Therapeutics shares in Q3 2025, an estimated $5.31M.
- Jacobs Levy Equity Management first reported a position in Sage Therapeutics in Q1 2016 and held it in 21 quarters.
- Jacobs Levy Equity Management's Sage Therapeutics position peaked at $20.3M in Q4 2020.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.